Format
Sort by
Items per page

Send to

Choose Destination

Best matches for dexmethylphenidate hydrochloride:

Search results

Items: 1 to 20 of 70

1.
2.

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS.

J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721.

3.

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.

Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM.

JAMA Oncol. 2017 Jul 1;3(7):961-968. doi: 10.1001/jamaoncol.2016.6914. Review.

4.

Development of a refill pattern method to measure polypharmacy in administrative claims databases.

Liu X, Kubilis P, Bussing R, Winterstein AG.

Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1407-1413. doi: 10.1002/pds.4082. Epub 2016 Aug 16.

PMID:
27528378
5.

Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.

Sayer GR, McGough JJ, Levitt J, Cowen J, Sturm A, Castelo E, McCracken JT.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):882-888. Epub 2016 Aug 2.

6.

Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Patrick KS, Straughn AB.

Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. Epub 2016 Jan 4.

7.

The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.

Perugi G, Vannucchi G.

Expert Opin Pharmacother. 2015;16(14):2193-204. doi: 10.1517/14656566.2015.1079620. Review.

PMID:
26364896
8.

Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder.

Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, Haynes VS, Escobar R, Upadhyaya H.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1611-21. doi: 10.1016/j.euroneuro.2015.06.003. Epub 2015 Jun 22. Review.

9.

Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Malcolm R.

J Clin Psychopharmacol. 2015 Aug;35(4):464-7. doi: 10.1097/JCP.0000000000000348.

10.
11.

Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.

Sugrue D, Bogner R, Ehret MJ.

Am J Health Syst Pharm. 2014 Jul 15;71(14):1163-70. doi: 10.2146/ajhp130638. Review.

PMID:
24973373
12.

Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr.

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):238-44. doi: 10.1089/cap.2013.0102. Epub 2014 May 9.

13.

Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011.

Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS.

Am J Manag Care. 2014 Mar 1;20(3):e90-7.

14.
15.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Nov;16(11):1275-89. doi: 10.3111/13696998.2013.839947. Epub 2013 Sep 19.

PMID:
24004347
16.

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.

Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Oct;16(10):1203-15. doi: 10.3111/13696998.2013.832258. Epub 2013 Aug 23.

PMID:
23937642
17.

Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.

Silva RR, Brams M, McCague K, Pestreich L, Muniz R.

Clin Neuropharmacol. 2013 Jul-Aug;36(4):117-21. doi: 10.1097/WNF.0b013e31829aa92c.

PMID:
23860345
18.

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.

Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

J Med Econ. 2013 Jul;16(7):962-75. doi: 10.3111/13696998.2013.800524. Epub 2013 Jun 7.

PMID:
23621503
19.

Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.

Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, Martin P, Ermer J.

Drugs R D. 2013 Mar;13(1):53-61. doi: 10.1007/s40268-013-0009-5.

20.

Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Bell GH, Anderson ER, Malcolm RJ.

Drug Metab Dispos. 2013 Jan;41(1):197-205. doi: 10.1124/dmd.112.048595. Epub 2012 Oct 25.

Supplemental Content

Loading ...
Support Center